NADK inhibitors could represent clinically relevant drugs in cancer therapy, such as the lead compound thionicotinamide, an NADK inhibitor prodrug already assayed on human B-cell lymphoma and colon cancer xenograft mice [59]. Here, NADK is linked to B-cell non-Hodgkin lymphoma.